F3879
Fibrinogen from human plasma
50-70% protein (≥80% of protein is clottable)
Synonim(y):
Factor I
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Polecane produkty
pochodzenie biologiczne
human plasma
Formularz
powder
jakość
50-70% protein (≥80% of protein is clottable)
masa cząsteczkowa
α-chain 63.5 kDa
β-chain 56 kDa
γ chain 47 kDa (about 4% carbohydrate content)
soluble dimer 340 kDa
stężenie
50-70% protein (biuret)
metody
ELISA: suitable
rozpuszczalność
0.9% NaCl: soluble 10 mg/mL
temp. przechowywania
−20°C
Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów
Opis ogólny
Fibrinogen, or Factor I, is a blood protein that is involved in clotting and is converted to fibrin by thrombin. Fibrinogen has an approximate molecular weight of 340 kDa
Zastosowanie
Fibrinogen was used in the induction of release of TNF-like cytotoxic factor from murine macrophages. It was used for fabrication of fibrin scaffolds with controlled microscale architecture by a two-photon polymerization-micromolding technique.
Fibrinogen was also used in the development of a fibrinogen-specific sandwich enzyme-linked immunosorbent assay microarray assay for distinguishing between blood plasma and serum samples.
Fibrinogen from human plasma has been used-
Fibrinogen was also used in the development of a fibrinogen-specific sandwich enzyme-linked immunosorbent assay microarray assay for distinguishing between blood plasma and serum samples.
Fibrinogen from human plasma has been used-
- for the production of fibrin hydrogels
- for the preparation of fibrin-MSCs (mesenchymal stem cells)-cartilage constructs
- for analyzing the protein repellent properties of PFDA-co-DEGDME (diethyleneglycol dimethyl ether) surface using Quartz crystal microbalance (QCM)
Działania biochem./fizjol.
Acute phase protein that is part of the coagulation cascade of proteins.
Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.
Charakterystyka techniczna
Source material has tested negative for HIV and HBsAg.
Postać fizyczna
Lyophilized powder containing ~15% sodium citrate and ~25% sodium chloride.
Rekonstytucja
The optimal way to solubilize fibrinogen is to layer it on top of warm (37 ºC) saline, as fibrinogen will not dissolve in water. The saline concentration can be in the range of 0.85-0.9%. The fibrinogen-saline solution can be gently agitated, but it must not be vortexed. The fibrinogen will slowly dissolve to give a hazy solution. Fibrinogen may be sterile-filtered, but may not go through a 0.1 μ filter. A 0.2 μ filter is suggested, with positive pressure using a syringe and "button" filter. Vacuum filtration should not be used, since this will lead to breakdown of the molecule during the filtration.
Komentarz do analizy
Protein determined by biuret
Oświadczenie o zrzeczeniu się odpowiedzialności
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Środki ochrony indywidualnej
Eyeshields, Gloves, type N95 (US)
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
Amphiphilic Copolymer Coatings via Plasma Polymerisation Process: Switching and Anti-Biofouling Characteristics.
Kumar V, et al.
Plasma Processes and Polymers, 8, 373-385 (2011)
L J Walsh et al.
Journal of dental research, 65(12), 1424-1426 (1986-12-01)
T6 is an antigen which is a highly specific marker for Langerhans cells. Previous studies have demonstrated that Interleukin-1 (IL-1) and an IL-1 inhibitor (ILS) modulate T6 expression (T6E) in explant culture. The present study examined the effects of IL-1
Varanid Lizard Venoms Disrupt the Clotting Ability of Human Fibrinogen through Destructive Cleavage.
James S Dobson et al.
Toxins, 11(5) (2019-05-10)
The functional activities of Anguimorpha lizard venoms have received less attention compared to serpent lineages. Bite victims of varanid lizards often report persistent bleeding exceeding that expected for the mechanical damage of the bite. Research to date has identified the
Dwin Grashof et al.
Toxins, 12(2) (2020-02-06)
Envenomations are complex medical emergencies that can have a range of symptoms and sequelae. The only specific, scientifically-validated treatment for envenomation is antivenom administration, which is designed to alleviate venom effects. A paucity of efficacy testing exists for numerous antivenoms
Anastasia Koroleva et al.
Biofabrication, 4(1), 015001-015001 (2012-01-20)
Fabrication of three-dimensional (3D) fibrin scaffolds with tightly controllable pore sizes and interconnections has been investigated. The scaffolds were produced using a combination of two-photon polymerization (2PP) and micromolding techniques. Master structures were fabricated by 2PP and regenerated in fibrin
Produkty
We will explore the technological advances that have contributed toward the progress of 3DP of tissue engineering scaffolds, current materials used to create 3DP scaffolds, and the challenges that remain.
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej